<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02023151</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00081287</org_study_id>
    <nct_id>NCT02023151</nct_id>
  </id_info>
  <brief_title>Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils</brief_title>
  <official_title>Predicting the Clinical Response to Omalizumab With Anti-IgE Response or Syk Expression in Basophils</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to test whether differences in blood cells at baseline (start of
      the study) can be used to predict how well omalizumab will work in a patient. Omalizumab
      (Xolair) is a drug approved by the U.S. Food and Drug Administration (FDA) to treat asthma.
      Studies show that omalizumab improves the symptoms of asthma but some people experience
      better improvement than others.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      From a therapeutic perspective, the study will determine whether changes in the peripheral
      blood basophil response to crosslinking anti-IgE Ab during treatment with omalizumab predicts
      the clinical efficacy of treatment with the drug. Secondary outcomes measures would focus on
      whether the starting level of anti-IgE-mediated histamine release, or the changes syk
      expression or its starting level would be sufficient to predict the clinical outcome.

      The study is a single-site trial to evaluate the utility of baseline basophil measures to
      predict the efficacy of subcutaneously administered omalizumab as an add-on therapy for the
      treatment of adult patients 18âˆ’75 years old who have been diagnosed with moderate to severe
      asthma according to current approved guidelines. Patients will be treated with omalizumab
      according to the standard FDA approved dosing table for a period of 16 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the Peripheral Blood Basophil Response to Crosslinking Anti-IgE Ab</measure>
    <time_frame>baseline and 26 weeks</time_frame>
    <description>Data will be analyzed for the fold change in the in vitro anti-IgE-mediated histamine release response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Syk Expression</measure>
    <time_frame>baseline and 26 weeks</time_frame>
    <description>Change in syk expression. Syk is a signaling molecule that is the first downstream event in IgE receptor activation of basophils.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Allergic Asthma</condition>
  <arm_group>
    <arm_group_label>Omalizumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Active</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <arm_group_label>Omalizumab</arm_group_label>
    <other_name>xolair</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with moderate-to-severe asthma; male and females aged 18-75 who are
             symptomatic despite treatment with inhaled corticosteroids if they also had an asthma
             duration &gt; 1 year.

          -  Positive blood testing to at least one common allergen (including must mite, D. F. and
             D. P., cockroach, dog or cat)

          -  Serum IgE within the bounds of the dosing table (&gt;30 IU/ml to &lt; 700 IU/ml)

          -  Reversibility of &gt; 12% within 30 minutes after administration of albuterol or history
             of reversibility in past or history of positive methacholine in past

          -  Baseline Forced expiratory volume (FEV1) of &gt; 0% and &lt; 80% of predicted

          -  Treatment with 400 to 800 ug day of beclomethasone dipropionate or its equivalent.

          -  Patients must be willing to give written informed consent and be able to adhere to
             dose and visit schedules and meet trial requirements.

          -  Patients will be excluded if they have prior sensitivity to omalizumab, and acute
             respiratory tract infection prior to or during the run-in period, or a need for
             regular B-agonist use.

        Exclusion Criteria:

          -  Treatment with an investigational agent within 30 days of screening

          -  Previously treated with omalizumab within a year prior to screening

          -  Treatment 1 month prior to screening with: hydroxychloroquine, methotrexate,
             cyclosporine, cyclophosphamide, intravenous immunoglobulin G, and plasmapheresis

          -  Clinically relevant laboratory anomalies at screening including individuals with
             reduced hematocrit (&lt;32%), White Blood Cell (WBC) count (2400/microliter), platelet
             count (&lt; 75000/microliter), and increased creatinine (&gt; 141.4 micromolar/L), or
             aminotransferase (AST) (&gt;100 IU/L).

          -  Patients with current malignancy, history of malignancy, or currently under work-up
             for suspected malignancy, or bleeding disorder.

          -  History of any medical condition that is unstable

          -  Inability to comply with study and follow-up procedures

          -  Patients may not take systemic corticosteroids within 2 weeks prior to screening\

          -  Women of childbearing potential who are pregnant or nursing mothers, or who are of
             childbearing potential (post-menarche) and are not practicing an acceptable form of
             contraception ( as determined by the site investigator)

          -  Individuals with body weight less than 30 kg or greater than 150 kg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarbjit S. Saini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Asthma &amp; Allergy Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2013</study_first_submitted>
  <study_first_submitted_qc>December 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2013</study_first_posted>
  <results_first_submitted>July 31, 2017</results_first_submitted>
  <results_first_submitted_qc>November 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2017</results_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Omalizumab</title>
          <description>Active
Omalizumab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Omalizumab</title>
          <description>Active
Omalizumab</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in the Peripheral Blood Basophil Response to Crosslinking Anti-IgE Ab</title>
        <description>Data will be analyzed for the fold change in the in vitro anti-IgE-mediated histamine release response</description>
        <time_frame>baseline and 26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab</title>
            <description>Active
Omalizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Peripheral Blood Basophil Response to Crosslinking Anti-IgE Ab</title>
          <description>Data will be analyzed for the fold change in the in vitro anti-IgE-mediated histamine release response</description>
          <units>Fold change in basophil Syk expression</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Syk Expression</title>
        <description>Change in syk expression. Syk is a signaling molecule that is the first downstream event in IgE receptor activation of basophils.</description>
        <time_frame>baseline and 26 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab</title>
            <description>Active
Omalizumab</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Syk Expression</title>
          <description>Change in syk expression. Syk is a signaling molecule that is the first downstream event in IgE receptor activation of basophils.</description>
          <units>fold change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread=".4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>26 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Omalizumab</title>
          <description>Active
Omalizumab</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small study with difficult enrollment</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Sarbjit Saini</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>4105502191</phone>
      <email>ssaini@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

